Background {#Sec1}
==========

The European chemicals' legislation REACH (EU 1907/2006) \[[@CR1]\] aims to protect man and the environment from substances of very high concern (SVHC). Chemicals with (very) persistent, (very) bioaccumulative, and toxic properties (PBT and vPvB compounds), substances that are carcinogenic, mutagenic, and toxic to reproduction (CMR compounds), as well as chemicals of equivalent concern like endocrine disruptors (EDs), see Box [1](#Taba){ref-type="table"}, and sensitizers may be subject to authorization.Box 1Definition of endocrine disruptorsAn **Endocrine Disruptor** is an *"exogenous substance or mixture that* ***alters function(s) of the endocrine system*** *and* ***consequently*** *causes* ***adverse health effects*** *in an intact organism, or its progeny, or (sub)populations,"* according to the widely accepted WHO/IPCs definition. The REACH regulation does not use the term "Endocrine Disruptors" but refers to "substances---such as those **having endocrine disrupting properties** \[...\]---for which there **is scientific evidence of probable serious effects** to human health or the environment which **give rise to an equivalent level of concern**" compared to CMR and PBT/vPvB substances (Art 57f). However, the WHO/IPCS definition has been used for the identification of EDs as substances of very high concern and was confirmed to be the base for SVHC identification by the European Commission in its communication with regard to Endocrine Disruptors in June 2016 (<http://ec.europa.eu/health/endocrine_disruptors/docs/com_2016_350_en.pdf>)

The Roadmap 2020, proposed by the European Commission in February 2013, asks all European Member States and the European Chemicals Agency (ECHA) to consider by 2020 which hazardous chemicals may be SVHC \[[@CR2]\]. In this context, identification of potential EDs is restricted because specific experimental assessments are not standard requirements under REACH.

The OECD tiered conceptual framework for testing and assessment of EDs \[[@CR3]\] involves OECD test guidelines and standardized test methods that can be used to evaluate chemicals for endocrine disruption. The guidance provides five levels of mammalian and non-mammalian toxicology using existing data and non-test information (level 1), in vitro (level 2) and in vivo (level 3) assays of selected endocrine mechanisms and pathways, in vivo assays providing data on adverse effects on endocrine relevant endpoints (level 4), and in vivo effects over more extensive parts of the life cycle of the organisms (level 5). Respective data are, however, available only for a limited number of chemicals.

Many currently known EDs operate via sexual endocrine pathways, and estrogenic (E) and androgenic (A) EDs (EA-EDs), agonists and antagonists, are thus an important group of possible SVHC candidates under REACH. The screening for potential EDs with regard to the environment to identify SVHC candidates is currently based on a combination of observations from in vitro and/or in vivo experiments (if available), structural analogy with known EDs, and expert judgement. The evaluation of information inherent to the chemical structures of the compounds is an appropriate starting point without the immediate need for animal experiments. Key to chemical structure-based approaches is the paradigm that similar chemical structures have similar properties and effects. However, chemical similarity is a complex and context-dependent phenomenon. Regarding estrogenic or androgenic activities, similar chemicals share one or several chemical patterns related to EA receptor interactions, the so-called structural alerts \[[@CR4]--[@CR19]\]. If a structural alert for potential ligands of EA receptors, acting as agonists or antagonists, is present in a compound, there is evidence that it may be EA-ED and closer inspection may be warranted.

The present study addresses screening for EA-EDs in fish based on evidence from structural alerts and in vitro and in vivo toxicological assays:review and refinement of structural alerts for the indication of potential estrogenic and androgenic endocrine activities based on in vitro studies;analysis of in vivo mammalian long-term reproduction studies with regard to estrogen- and androgen-sensitive endpoints in order to identify potential indicators for endocrine activity with regard to the environment;consistency of potential estrogenic and androgenic endocrine activities based on in vitro assays and in vivo mammalian long-term reproduction studies and fish life-cycle tests; andevaluation of structural alerts, in vitro assays, and in vivo mammalian long-term reproduction studies for the indication of potential estrogenic and androgenic endocrine disruptors in fish.

The results of this study have been used to develop a computerized screening tool for the German Environment Agency (Umweltbundesamt, UBA) to identify potential EA-EDs with regard to the environment based on structural alerts related to binding to estrogen and androgen receptors. Other endocrine mechanisms, for example, interference with thyroid hormones or steroidogenesis, damage of the corticosteroid system or the immune system, or epigenetic effects, are not regarded in this study.

Elements of the screening tool are used for a computerized mass screening performed by ECHA \[[@CR20]\]. The mass screening is part of a common screening approach developed by ECHA and Member States aiming at identifying those substances which might be subject to further evaluation or risk management measures. The mass screening includes hazard-based indicators such as structural alerts but also considers potential emissions to man and the environment. In a second step, substances identified during mass screening are manually screened by member states, taking into account additional information, with the aim to decide whether or not further information is needed to conclude on the hazard potential. If information is missing to conclude on the endocrine-disrupting properties, the chemical may become subject to substance evaluation under REACH, a process permitting to request non-standard information on endocrine-disrupting properties. If substance evaluation confirms endocrine disruption, further regulatory action such as identification as SVHC and eventually restriction or the need for application for authorization might be triggered.

Results and discussion {#Sec2}
======================

Screening for potential endocrine disruptors in fish was approached based on evidence from structural alerts and in vitro and in vivo toxicological assays. First, structural alerts for the indication of potential estrogenic and androgenic endocrine activities were reviewed and refined based on in vitro studies. Then, consistencies between in silico structural alerts, in vitro assays, and in vivo mammalian long-term reproduction studies and fish life-cycle tests were assessed. Finally, the model was applied to EINECS to search for potential candidates for estrogenic and androgenic effects with regard to the environment.

Review and refinement of structural alerts for the indication of potential estrogenic and androgenic endocrine activities based on in vitro studies {#Sec3}
---------------------------------------------------------------------------------------------------------------------------------------------------

### In vitro data collection {#Sec4}

Data from in vitro tests on estrogenic and androgenic effects (the so-called sexual endocrine effects) were retrieved from established databases \[[@CR4], [@CR21]\] and the literature (see Additional file [1](#MOESM1){ref-type="media"}). The focus was on tests based on receptor binding and receptor activation in cell cultures measured via reporter gene activation or cell proliferation:Competitive ligand-binding assays measure the binding affinity of a substance to an (isolated) receptor.Reporter gene assays measure activities of intact cells as a result of receptor-binding, for example mRNA, protein. The cells are transiently or permanently transfected with reporter gene systems.Cell proliferation assays measure cell proliferation triggered by receptor binding.

The collected dataset covers EA endocrine agonistic and antagonistic activities of 744 discrete chemicals. Substances were categorized based on their in vitro potencies in individual tests, relative receptor-binding affinities, or effect concentrations relative to positive controls, ethinylestradiol (estrogenic) or testosterone (androgenic), respectively (Table [1](#Tab1){ref-type="table"}). If several test results were available for the same compound, we used the highest reported in vitro potency. For a detailed description of the experimental data used to identify receptor-mediated EA endocrine activities of substances, see the "[Methods](#Sec12){ref-type="sec"}" section and Additional file [1](#MOESM1){ref-type="media"}.Table 1Overview of relative in vitro EA endocrine potencies (agonistic and antagonistic) of test substancesActivityRelative potencyNumber of substancesVery high≥135High0.1--166Moderate0.001--0.1110Weak0.00001--0.00196Very weak/inactive\<0.00001437Total number of substances744Relative potency: substances were categorized based on their in vitro potencies in individual tests, relative receptor-binding affinities, or effect concentrations relative to positive controls, ethinylestradiol (estrogenic) or testosterone (androgenic), respectively

Many chemicals are potential ligands of both, the estrogen and androgen receptors. Substantial similarity of EA receptors regarding their binding sites can be assumed. Only a few chemical classes interact only with one of these receptor families, such as phthalates \[[@CR5]\]. Because any kind of binding of xenobiotics to estrogen or androgen receptors is undesirable, we pooled the results from studies with both receptor types for the identification of relevant structural alerts. With the same reasoning, we did not differentiate between agonistic and antagonistic activities, since binding to the receptor is a prerequisite for both activities.

### Analysis of available structural alerts {#Sec5}

The collected dataset of estrogenic and androgenic activities in vitro provided a comprehensive basis to analyze and define structural alerts that can be used to screen for potential EA-EDs (Table [2](#Tab2){ref-type="table"}). First, we tested the applicability of structural alerts reported in the literature \[[@CR1]--[@CR17]\] like, for example, steroids, phytoestrogens, diphenylmethanes, biphenyls, bisphenols, phthalates, and alkylphenols (for details, see Additional file [2](#MOESM2){ref-type="media"}). The existing structural alerts identified many potential EA-EDs, but also resulted in a considerable fraction of false negatives with active EA-EDs not detected. False negatives are particularly critical because they could result in severe problems if adequate precaution was then not taken.Table 2Performance of structural alerts for EA-EDs based on the number of substances with endocrine activity that contain the structural alert \[Actives (true positives)\] relative to the number of substances without endocrine activity that contain the same structural alert \[Inactives (false positives)\](Table extracted from the project report \[[@CR26]\])Structural alertStructureSMILESActives (true pos.)Inactives (false pos.)% activesRelevance for EA-ED screeningCommentsRef.SA 01![](12302_2016_94_Figa_HTML.gif){#d30e632}C1CCC4C(C1)C2C(C3C(CC2)CCC3)CC456887X\[[@CR4], [@CR7], [@CR8]\]SA 02![](12302_2016_94_Figb_HTML.gif){#d30e670}c1ccc3c(c1)C2C(CCCC2)CC3190100Covered by SA 01\[[@CR11]\]SA 03![](12302_2016_94_Figc_HTML.gif){#d30e702}c1ccc2c(c1)C(C(C)CC2)C210100X\[[@CR40]\]SA 04![](12302_2016_94_Figd_HTML.gif){#d30e734}c1cccc(c1)C=Cc2ccc(cc2)O14193X\[[@CR4]\]SA 05![](12302_2016_94_Fige_HTML.gif){#d30e766}c1cccc(c1)CCc2ccc(cc2)O17289X\[[@CR4], [@CR7]\]SA 06![](12302_2016_94_Figf_HTML.gif){#d30e801}c1cccc(c1)CCc2ccccc218869More false positives than SA 05\[[@CR5], [@CR8]\]SA 07![](12302_2016_94_Figg_HTML.gif){#d30e836}c1cccc(c1)C(=Cc2ccccc2)c3ccccc380100X\[[@CR4]\]SA 08![](12302_2016_94_Figh_HTML.gif){#d30e868}C3(c1ccccc1)Oc2c(cccc2)C(C=3)=O8753\[[@CR4]\]SA 09![](12302_2016_94_Figi_HTML.gif){#d30e898}C3(c1ccccc1)Oc2c(cccc2)C(C3)=O5456\[[@CR4]\]SA 10![](12302_2016_94_Figj_HTML.gif){#d30e928}C3(c1ccccc1)C(c2c(cccc2)OC3)=O00\[[@CR4]\]SA 11![](12302_2016_94_Figk_HTML.gif){#d30e956}C3(c1ccccc1)=Cc2c(cccc2)OC3=O10100X\[[@CR4]\]SA 12a![](12302_2016_94_Figl_HTML.gif){#d30e989}C(c1ccccc1)CC(c2ccccc2)=O7464\[[@CR4]\]SA 12b![](12302_2016_94_Figm_HTML.gif){#d30e1019}O=C(c(cccc1)c1)C=Cc(cccc2)c212860X\[[@CR4]\]SA 13![](12302_2016_94_Fign_HTML.gif){#d30e1051}C2C(c1c(cc(cc1O(\[H\]))O(\[H\]))CCCCCCCCCC2)=O00\[[@CR4]\]SA 14![](12302_2016_94_Figo_HTML.gif){#d30e1079}c1cccc(c1)Cc2ccccc2463557\[[@CR4], [@CR5]\]SA 15a![](12302_2016_94_Figp_HTML.gif){#d30e1112}c1cccc(c1O(\[H\]))C(c2ccccc2)=O3730\[[@CR4], [@CR5], [@CR7], [@CR16]\]SA 15b![](12302_2016_94_Figq_HTML.gif){#d30e1151}c1(cccc(c1)C(c2ccccc2)=O)O\[H\]020\[[@CR4], [@CR5], [@CR7], [@CR16]\]SA 15c![](12302_2016_94_Figr_HTML.gif){#d30e1190}c1c(ccc(c1)C(c2ccccc2)=O)O\[H\]4180X\[[@CR4], [@CR5], [@CR7], [@CR16]\]SA 16![](12302_2016_94_Figs_HTML.gif){#d30e1231}c1cccc(c1)C(c2ccccc2)=C(Cl)Cl60100X\[[@CR4], [@CR18]\]SA 17![](12302_2016_94_Figt_HTML.gif){#d30e1266}c1cccc(c1)C(c2ccccc2)C191556XCoverage of, e.g., DDT analogues\[[@CR7], [@CR17]\]SA 18![](12302_2016_94_Figu_HTML.gif){#d30e1303}c1ccccc1c2ccccc2111444X\[[@CR5]--[@CR7], [@CR12], [@CR13], [@CR16], [@CR19]\]SA 19a![](12302_2016_94_Figv_HTML.gif){#d30e1351}c1ccccc1c2c(cccc2)Cl6275X\[[@CR4]\]SA 19b![](12302_2016_94_Figw_HTML.gif){#d30e1384}c1ccccc1c2cc(ccc2)Cl4357XAnalogy with SA 19a and 19c\[[@CR4]\]SA 19c![](12302_2016_94_Figx_HTML.gif){#d30e1418}c1ccccc1c2ccc(cc2)Cl6367X\[[@CR4]\]SA 20a![](12302_2016_94_Figy_HTML.gif){#d30e1450}c1ccccc1c2c(cccc2)O\[H\]010\[[@CR4]\]SA 20b![](12302_2016_94_Figz_HTML.gif){#d30e1480}c1ccccc1c2cc(ccc2)O\[H\]010\[[@CR4]\]SA 20c![](12302_2016_94_Figaa_HTML.gif){#d30e1510}c1ccccc1c2ccc(cc2)O\[H\]60100X\[[@CR4]\]SA 21![](12302_2016_94_Figab_HTML.gif){#d30e1542}c1ccc2c(c1)Oc3c(O2)cccc310100X\[[@CR12]\]SA 22![](12302_2016_94_Figac_HTML.gif){#d30e1574}c1ccc2c(c1)oc3c2cccc300\[[@CR12]\]SA 23![](12302_2016_94_Figad_HTML.gif){#d30e1602}c1ccc(c(c1)C(OC)=O)C(=O)OC7654X\[[@CR5], [@CR7], [@CR18]\]SA 24![](12302_2016_94_Figae_HTML.gif){#d30e1640}c1cc(ccc1C(OC)=O)O\[H\]16289X\[[@CR4], [@CR5]\]SA 25a![](12302_2016_94_Figaf_HTML.gif){#d30e1675}c1c(c(ccc1)O(\[H\]))OC3350\[[@CR4]\]SA 25b![](12302_2016_94_Figag_HTML.gif){#d30e1705}O(C)c1cc(ccc1)O\[H\]151747\[[@CR4]\]SA 25c![](12302_2016_94_Figah_HTML.gif){#d30e1736}O(C)c1ccc(cc1)O\[H\]7370X\[[@CR4]\]SA 26![](12302_2016_94_Figai_HTML.gif){#d30e1768}c1cc(ccc1)O\[H\]1319857Specified phenols: see SA 04, SA 05, SA 15, SA 20, SA 25, SA 34\[[@CR5], [@CR7]--[@CR11], [@CR14]--[@CR16], [@CR18], [@CR40]\]SA 27![](12302_2016_94_Figaj_HTML.gif){#d30e1819}C1(=O)CCCCC17464\[[@CR40]\]SA 28![](12302_2016_94_Figak_HTML.gif){#d30e1849}c1cccc(c1)C(c2ccccc2)c3ccccc31517\[[@CR7]\]SA 29![](12302_2016_94_Figal_HTML.gif){#d30e1879}c1c(ccc(c1)S(c2ccc(cc2)O(\[H\]))(=O)=O)O\[H\]010\[[@CR7]\]SA 30a![](12302_2016_94_Figam_HTML.gif){#d30e1909}c1c(ccc(c1)Oc2c(cc(cc2)Cl)Cl)Cl20100X\[[@CR18]\]SA 30b![](12302_2016_94_Figan_HTML.gif){#d30e1941}c1c(ccc(c1)Oc2c(cc(cc2)Cl)Cl)N(=O)=O40100X\[[@CR18]\]SA 31a![](12302_2016_94_Figao_HTML.gif){#d30e1973}c1cccc(c1)CN2C(c3c(C2=O)cccc3)=O1150\[[@CR7]\]SA 31b![](12302_2016_94_Figap_HTML.gif){#d30e2003}c1c(ccc(c1)CN2C(c3c(C2=O)cccc3)=O)N(=O)=O00\[[@CR7]\]SA 31c![](12302_2016_94_Figaq_HTML.gif){#d30e2031}c1c(ccc(c1)CN2C(c3c(C2=O)cccc3)=O)O\[H\]10100X\[[@CR7]\]SA 32a![](12302_2016_94_Figar_HTML.gif){#d30e2063}c1cccc(c1)OP(=O)(OC)OC10100X\[[@CR7]\]SA 32b![](12302_2016_94_Figas_HTML.gif){#d30e2096}c1cccc(c1)OP(=S)(OC)OC3175X\[[@CR7]\]SA 33![](12302_2016_94_Figat_HTML.gif){#d30e2128}c1nc(N)nc(N)n1060\[[@CR7]\]SA 34a![](12302_2016_94_Figau_HTML.gif){#d30e2158}\[H\]Oc1ccc(C(\[H\])C)cc1391572XSpecified from SA 26SA 34b![](12302_2016_94_Figav_HTML.gif){#d30e2187}\[H\]Oc1ccc(C(C)(C)C(\[H\]))cc17944Specified from SA 26SA 34c![](12302_2016_94_Figaw_HTML.gif){#d30e2214}\[H\]Oc1c(\[H\])c(\[H\])c(C(\[H\])C)c(\[H\])c(\[H\])123582XSpecified from SA 26SA 34d![](12302_2016_94_Figax_HTML.gif){#d30e2243}\[H\]Oc1c(\[H\])c(\[H\])c(C(C)(C)C(\[H\]))c(\[H\])c(\[H\])16275XSpecified from SA 26SA 35![](12302_2016_94_Figay_HTML.gif){#d30e2272}c(c(c(c(c1)ccc2)c2)ccc3)(c1)c313862XCoverage of certain active polyaromatic compoundsSA 36a![](12302_2016_94_Figaz_HTML.gif){#d30e2301}c1ccccc1CC=O283544\[[@CR7]\]SA 36b![](12302_2016_94_Figba_HTML.gif){#d30e2331}c1ccccc1CP=S00\[[@CR18]\]SA 37![](12302_2016_94_Figbb_HTML.gif){#d30e2359}c1ccccc1N2C(=O)CCC(=O)23175XSA 38![](12302_2016_94_Figbc_HTML.gif){#d30e2386}C1CCCCCCCCCCC13260XCoverage of HBCDsSA 39![](12302_2016_94_Figbd_HTML.gif){#d30e2416}CCCCC(\[H\])c1cc(OC)ccc15183XSA 40![](12302_2016_94_Figbe_HTML.gif){#d30e2443}CCCCC(\[H\])c1ccc(OC)cc190100XSA 41![](12302_2016_94_Figbf_HTML.gif){#d30e2470}c1c(C(F)(F)F)cccc1NC=O40100XSA 43![](12302_2016_94_Figbg_HTML.gif){#d30e2497}c1ccccc1COc2ccccc2161453XSA 46![](12302_2016_94_Figbh_HTML.gif){#d30e2524}C12C=CC(C2)CC18657XCoverage of norbornenesSA 47![](12302_2016_94_Figbi_HTML.gif){#d30e2553}C12CCC(C2)CC16275XCoverage of norbornenesSA 48a![](12302_2016_94_Figbj_HTML.gif){#d30e2582}c1(Br)ccccc1Oc1ccccc114288XCoverage of BDEsSA 48b![](12302_2016_94_Figbk_HTML.gif){#d30e2611}c1c(Br)cccc1Oc1ccccc111379XCoverage of BDEsSA 48c![](12302_2016_94_Figbl_HTML.gif){#d30e2640}c1cc(Br)ccc1Oc1ccccc117385XCoverage of BDEsSA 49![](12302_2016_94_Figbm_HTML.gif){#d30e2669}c12ccccc2CCC13175XRelevant structural alerts (X in column "Relevance for EA-ED screening") are present more in substances with endocrine activity than in substances without endocrine activity

### Development of improved structural alerts {#Sec6}

To improve the detection of potential EA-EDs, we identified more structural alerts by systematic inspections of the chemical structures of substances with endocrine activity, for example, brominated diphenyl ethers (BDEs) and hexabromocyclododecanes (HBCDDs) that are antagonists in EA receptor-binding assays \[[@CR22]\]. Furthermore, we looked for possible refinements of established structural alerts. The phenolic ring structure is an essential element of many EA-EDs; however, without further specifications it is not an indicative structural alert. Established "phenol" alerts explicitly address, for example, DES, biphenylols, or parabens \[[@CR4], [@CR5], [@CR7]\]. For additional improvements, we suggest *p*-alkyl substitution pattern to increase the detection of actives from less than 60% to more than 70% (see Table [2](#Tab2){ref-type="table"}, SA 34 as compared to SA 26).

The performance of existing and new structural alerts was evaluated with the collected dataset of estrogenic and androgenic activities in vitro based on the number of substances with endocrine activity that contain the structural alert ("true positives") relative to the number of substances without endocrine activity that contain the same structural alert ("false positives"). Table [2](#Tab2){ref-type="table"} lists the structural alerts together with their occurrences in either active or inactive substances. Generally, a structural alert is considered a relevant EA-ED indicator (X in column "relevance for EA-ED screening") if it could be found more often in active substances than in inactive substances. An empirical threshold of two-thirds was used to balance between too many "false positives" and too many "false negatives". A few structural alerts with lower percentage of actives were included when either addressing very potent EA-EDs or covering large numbers of actives. Some structural alerts with high percentage of actives were not included because very similar structural alerts were available with even better performance (see Table [2](#Tab2){ref-type="table"}, for example SA 6 as compared to SA 4 and 5). Some structural alerts could not be evaluated because they are not represented by the chemicals of the collected dataset of estrogenic and androgenic activities in vitro (see Table [2](#Tab2){ref-type="table"}, for example SA 10, 13, 22, 31b, 36b).

The structural alerts (Table [2](#Tab2){ref-type="table"}) classify 257 of 307 (84%) substances with endocrine activity in vitro as "true positives". The presence of a relevant structural alert thus clearly indicates potential EA receptor agonists and antagonists. These are priority pollutants to undergo further assessments of their potential for endocrine activities. At the same time, the structural alerts indicate 100 of 437 (23%) substances without endocrine activity in vitro as false positives. False-positive predictions may lead to additional testing to show the absence of EA activities. Concern is related to false negatives \[50 of 307 (16%)\], chemicals with EA endocrine activities in vitro, but not recognized by structural alerts. Closer inspection of the 50 chemicals with false-negative predictions of EA-ED activities (for details, see Additional file [3](#MOESM3){ref-type="media"}) reveals 16 compounds with only (very) weak in vitro potencies according to the in vitro test results. With regard to prioritization of hazardous substances, these compounds may be considered less relevant. More significant are outliers with moderate (*n* = 26), high (*n* = 6), and very high (*n* = 2) in vitro potencies. Notably, among the eight (very) highly potent compounds are six antiandrogens like linuron and cypermethrin. For example, linuron is a weak in vivo AR antagonist that causes antiandrogenic activity via enzymatic pathway inhibition \[[@CR23]\] and thyreotoxicity \[[@CR24]\]. Impairment of thyroidal function has profound effects on fetal development and postnatal maturation and may mask EA-mediated effects. The 26 false-negative outliers of moderate in vitro potency are chemically diverse, including several pharmaceuticals and pesticides. The search for relevant structural alerts to detect these compounds was not successful. Another influential factor may be related to uncertainties of individual test results. Although the data were taken from peer-reviewed literature and quality-checked databases, "outliers" cannot be excluded.

It is important to note that the structural alerts are only indicators of the potential of chemical substances to be ligands of estrogen or androgen receptors. It is not possible to conclude mode and strength of potential agonistic or antagonistic activities. Furthermore, chemicals acting by other endocrine pathways will not be recognized.

Analysis of in vivo mammalian long-term reproduction studies with regard to estrogen- and androgen-sensitive endpoints {#Sec7}
----------------------------------------------------------------------------------------------------------------------

Long-term in vivo studies of the effects on reproduction and development of mammals may include effects on endocrine systems. Symptoms like estrus cycle irregularities, reduced reproduction rate, or delayed sexual maturation may be due to systemic toxic effects, for example seen as decreased body weight, but also due to interferences with the endocrine system \[[@CR25]\]. Although causal links between the observed effects and endocrine disorders may be difficult to establish (Fig. [1](#Fig1){ref-type="fig"}), evaluation of existing information from repeated dose and multi-generation in vivo studies indicated several parameters related to potential endocrine disruption \[[@CR26]\] and can thus be used to inform about potential endocrine disruption with regard to the environment:Fig. 1Scheme for differentiation between general reproductive toxicity and interactions with endocrine systems based on a weight-of-evidence approach. *AGD* anogenital distance, *BW* body weight, *DHT* dihydrotestosterone, *FSH* follicle-stimulating hormone, *LH* luteinizing hormone, *PPS* preputial separation, *T3* tri-iodothyronine, *T4* thyroxine, *TSH* thyroid-stimulating hormone, *VO* vaginal opening malformation of reproductive organs, for example, agenesis/atrophic changes of testes, epididymis, and prostate;malformation and/or deviation of secondary sex characteristics, for example, hypospadia, male rodent nipple retention, and increased female anogenital distance;changes in serum hormone concentrations, for example, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen, and dihydrotestosterone (DHT); andeffects on the onset of puberty/sexual maturation, for example, delayed preputial separation.

As depicted in Fig. [1](#Fig1){ref-type="fig"}, deviation of only one parameter is in most cases not sufficient to conclude an endocrine activity. First, it should be evaluated if a secondary effect can be excluded, for example, due to changes in body weight. Second, it should be checked if further parameters are affected and the conclusion should be drawn based on a weight-of-evidence approach.

Reproductive toxicity data and subacute to chronic repeated dose toxicity studies were retrieved from the FedTex (<http://cefic-lri.org/lri_toolbox/fedtex/>) and the RepDose (<http://www.fraunhofer-repdose.de/>) databases. The FedTex and RepDose data were selected from the available literature based on the level of detail regarding, for example, description of study design and details given for results. The data were double-checked by a second expert. Screening for chemicals with positive effect parameters related to potential endocrine disruption resulted in a list of 240 organic compounds. These compounds are reproductive toxicants with a certain likelihood of endocrine disruption. An indication of the EA-EDs among the 240 compounds was obtained from a comparison with results from receptor-based in vitro assays. We observed about half of them to interact with EA receptors, indicating true positives that are toxic for reproduction and likely to have endocrine activities in mammals. Such substances are also potential endocrine disruptors with regard to the environment and further assessment of effects in fish might be needed. The other half of the 240 compounds are inactive in receptor-based in vitro assays and probably not EA-EDs in mammals.

Consistency of potential estrogenic and androgenic endocrine activities based on in vitro assays and in vivo mammalian long-term reproduction studies and fish life-cycle tests {#Sec8}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The predictive power of in vitro receptor binding and in vivo toxicity in mammals for endocrine activity in fish was assessed by comparing their outcome with results of reproduction and biomarker studies with fish, focusing on sexual endocrine endpoints, from an UBA report \[[@CR27]\] and the literature cited therein (see Table [3](#Tab3){ref-type="table"}). Population-relevant endpoints were addressed by full life-cycle and two-generation tests (FLC) focusing on the effect parameters reproduction (fertilized eggs, fertility rate), sexual development, and generation time. Partial life-cycle tests also address population-relevant effects on sexual development and reproduction. Indicative biomarkers for endocrine effects were investigated in the short-term fish screening assay (FSA) including vitellogenin and steroid hormone levels in blood. Regarding fish in vivo data, in total 22 studies (fish full life-cycle, partial life-cycle, and fish screening assays) were available for 12 substances. The effects of these 12 substances on fish were compared to the effects on mammals and in in vitro tests (Table [3](#Tab3){ref-type="table"}). Only for eight of them, also reproductive toxicity data for rodents were available. Receptor-based in vitro data could be retrieved for all the 12 substances. There is a remarkably good consistency of the data from fish and mammalian tests. The receptor-based in vitro activities support comparable sexual endocrine pathways of toxic action in fish and mammals. Combined assessment of data obtained in in vitro assays and in vivo fish tests reveals information on the underlying mechanism of action of the tested substance in fish, for example, reduced fertilization rate due to inhibition of androgen receptor activity in males.Table 3Comparison of in vivo long-term reproduction studies with mammals and fish with results from receptor-based in vitro assaysCompoundCAS no.MechanismMammalian reproductive toxicologyFish in vivo effectsReporter gene (cell) assaysReceptor-binding studiesFish full and partial life-cycle (FLC) testFish screening assay (FSA)Potency relative to positive controlPotency relative to positive controlIn vivo ED effect LOAELNOEC/EC~10~ populationNOEC indicator parameterEffectER agonistAR agonistAR antagonistERAR17-α Ethinylestradiol57-63-6ER agonistPos.-control in screening assays (OECD 440)0.3 ng/L, fertilization rate, delayed oviposition \[[@CR41]\]1 ng/L, ovotestis \[[@CR42]\]VTG increase \[[@CR27]\]Very active \[[@CR43]\]No \[[@CR28]\]Very active \[[@CR5]\]Moderate \[[@CR21]\]17-β Estradiol50-28-2ER agonist0.0025 mg/kg BW2.9 ng/L, fertilization rate, juvenile growth \[[@CR44]\]2.9 ng/L, VTG induction, males \[[@CR44]\]Very active \[[@CR45]\]Moderate \[[@CR28]\]Active \[[@CR18]\]Very active \[[@CR5]\]Active \[[@CR21]\]Tamoxifen10540-29-1ER antagonist0.00012 mg/kg BW1.6 µg/L, fertilization rate \[[@CR27]\]1.6 µg/L, VTG decrease, females \[[@CR27]\]VTG decrease \[[@CR27]\]Moderate \[[@CR43]\]Moderate \[[@CR46]\]Very active \[[@CR21]\]Active \[[@CR46]\]Genistein446-72-0ER agonist, enzyme inhibitor: aromatase1.25 mg/kg BW1.3 µg/L, fertilization rate, delayed oviposition \[[@CR27]\]Moderate \[[@CR47]\]Very active \[[@CR21]\]Moderate \[[@CR21]\]Methyl-testosterone58-18-4AR agonist10 ng/L, sex ratio \[[@CR48]\]\<0.4 ng/L, VTG decrease, females \[[@CR48]\]Active \[[@CR49]\]Active \[[@CR49]\]Very active \[[@CR21]\]17β-Trenbolone10161-33-8AR agonist1.68 mg/kg BW3 ng/L, sex ratio \[[@CR50]\]\<1 ng/L, histology: egg debris \[[@CR50]\]VTG and 11-keto-testosterone: no effect \[[@CR27]\]Active\[[@CR28]\]Very active \[[@CR21]\]Flutamide13311-84-7AR antagonist2.5 mg/kg BW189 µg/L, egg production \[[@CR27]\]435 µg/L, VTG decrease, females, 11-keto-testosterone: increase \[[@CR27]\]VTG no effect, 11-keto-testosterone: increase \[[@CR27]\]Weak \[[@CR28]\]Very active \[[@CR28]\]Moderate \[[@CR21]\]Bisphenol A80-05-7ER agonist0.0002 mg/kg BW390 µg/L, fertilization rate, delayed oviposition \[[@CR51]\] 160 µg/L, hatching rate of F1 generation \[[@CR52]\]1 µg/L, histology: testis, VTG increase, males \[[@CR52]\]VTG increase, 11-keto-testosterone: decrease \[[@CR27]\]Moderate \[[@CR53]\]Very weak \[[@CR54]\]Active \[[@CR18]\]Moderate \[[@CR5], [@CR21]\]Moderate \[[@CR21]\]4-*tert*-Pentylphenol80-46-6ER agonist100 µg/L, fertilization rate, sex ratio \[[@CR55]\]\<51 µg/L, VTG increase, males \[[@CR55]\]Active \[[@CR18]\]Moderate \[[@CR5], [@CR21]\]Moderate \[[@CR21]\]4-*tert*-Octylphenol140-66-9ER agonist11 µg/L, fertilization rate, delayed oviposition \[[@CR27]\]VTG increase, 11-keto-testosterone: decrease \[[@CR27]\]Moderate \[[@CR56]\]Very weak \[[@CR57]\]Active \[[@CR18]\]Moderate \[[@CR5], [@CR21]\]Moderate \[[@CR21]\]4-Nonylphenol84852-15-3ER agonist10 mg/kg BW8.2 µg/L, sex ratio, survival rate \[[@CR58]\]4.2 µg/L, gonadosomatic index \[[@CR58]\]Moderate \[[@CR59]\]Very weak \[[@CR60]\]Very weak \[[@CR60]\]Moderate \[[@CR21]\]Moderate \[[@CR21]\]Prochloraz (DMI fungicide)67747-09-5Aromatase inhibitor64 µg/L, sex ratio \[[@CR61]\]\<16 µg/L, VTG increase, males \[[@CR61]\]VTG decrease \[[@CR27]\]Very weak \[[@CR62]\]Very weak \[[@CR62]\]Mammalian reproductive toxicology from: <http://cefic-lri.org/lri_toolbox/fedtex/>, <http://www.fraunhofer-repdose.de/>Relative potencies in receptor-based in vitro assays: substances were categorized based on their in vitro potencies in individual tests, relative receptor-binding affinities, or effect concentrations relative to positive controls, ethinylestradiol (estrogenic) or testosterone (androgenic), respectively (Table [1](#Tab1){ref-type="table"})*LOAEL* lowest observed adverse effect level, *NOEC* no observed effect concentration, *ER* estrogen receptor, *AR* androgen receptor, *VTG* vitellogenin, *DMI fungicide* demethylation inhibitor (sterol synthesis inhibitor)

The substances identified as "endocrine active" in fish tests are reproductive toxicants in mammals and EA receptor ligands in in vitro assays (Table [3](#Tab3){ref-type="table"}). There are no false-negative results; however, the relative potencies vary. For example, flutamide is a moderate AR agonist in in vivo fish FLC tests \[[@CR27]\], very active in in vitro reporter gene assays \[[@CR28]\], and causes malformations in epididymis, seminal vesicles, prostate, Cowper's glands, and penis in rodents \[[@CR29]\]. It furthermore affects male secondary sexual characteristics in terms of feminization, impairs spermatogenesis, and alters pituitary hormone concentrations \[[@CR30]\].

Evaluation of structural alerts, in vitro assays, and in vivo mammalian long-term reproduction studies for the indication of potential estrogenic and androgenic endocrine disruptors in fish {#Sec9}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comparative analyses of the agreement of chemical and toxicological approaches to the identification of potential EA-EDs in fish were based on receptor-based in vitro assays and in vivo mammalian long-term reproduction studies. The combined dataset includes 933 chemicals, with 693 having only in vitro data and 189 having only in vivo mammalian long-term reproduction data. For 51 substances, in vivo as well as in vitro data were available. The minor overlap of the in vivo and in vitro datasets with only 51 chemicals shows that for many in vivo reproductive toxicants in rodents, the corresponding in vitro results that could specify the relevant modes of action have not been published.

The results of pairwise comparisons of the in vivo mammalian long-term reproductive toxicities and in vitro classifications with structural alerts of potential EA-EDs were quantified in terms of accuracy (proportion of substances correctly classified), sensitivity (proportion of true positives correctly classified), and specificity (proportion of true negatives correctly classified); for details, see "[Methods](#Sec12){ref-type="sec"}" section.

The structural alerts agree quite well (80% accuracy) with the in vitro classifications (Table [4](#Tab4){ref-type="table"}). This was to be expected since the structural alerts were derived from in vitro data. 16.3% (50 of 307) of the active chemicals in vitro are false negatives not recognized by the structural alerts. From the inactive chemicals in vitro, 22.9% (100 of 437) have the structural alerts and thus are false positives. Notably, performance of the structural alerts is better for chemicals with higher activity in vitro, and (very) high activities are classified more accurately than moderate to (very) weak activities.Table 4Comparison of in vitro activities and structural alerts of potential EA-EDs (numbers of chemicals, *n* = 744)In vitro very high activityIn vitro high activityIn vitro moderate activityIn vitro weak activityIn vitro very weak or no activityΣStructural alert = yes33608480100357Structural alert = no262616337387Σ356611096437744Accuracy = 79.8% (overall agreement)Sensitivity = 83.7% (→16.3% false-negative classifications)Specificity = 77.1% (→22.9% false-positive classifications)

Comparison of the classifications of the 51 chemicals tested in vivo and in vitro (Table [5](#Tab5){ref-type="table"}) shows that in vitro classifications always coincide with in vivo mammalian long-term reproductive toxicities. If we see in vitro activity, we always also see reproductive toxicity in vivo. Thus, based on these results, positive results in receptor-based in vitro assays are good indicators of possible reproductive toxicity in vivo and suggest that EA receptor binding may be involved in the reproductive toxicity of these compounds (24 of 48, corresponding to 50% true positives). At the same time, inactivity in vitro is not a good indicator for the absence of reproductive toxicity in vivo. The reproductive toxicity of compounds without EA receptor-binding potential is likely due to other modes of action.Table 5Comparison of in vivo mammalian long-term reproductive toxicities and in vitro activities of potential EA-EDs (numbers of chemicals, *n* = 51)In vitro very high activityIn vitro high activityIn vitro moderate activityIn vitro weak activityIn vitro very weak or no activityΣIn vivo active661112448In vivo inactive000033Σ661112751Accuracy = 52.9% (overall agreement)Sensitivity = 100% (→no false-negative classifications)Specificity = 50.0% (→50% false-positive classifications)Mammalian long-term reproductive toxicants: in vivo active: causing specific endpoints indicative for endocrine activity, in vivo inactive: not causing specific outcomes in the available study/studies

For an overview of the relationships between chemical and toxicological approaches to the identification of potential EA-EDs, we calculated classification statistics of pairwise comparisons of in vivo mammalian long-term reproductive toxicities, receptor-based in vitro activities, and structural alerts of potential EA-EDs. Table [6](#Tab6){ref-type="table"} summarizes the overall agreement, sensitivities, and specificities either for the full datasets (*n* = 744 or *n* = 240 for the receptor-based in vitro activities or the in vivo mammalian long-term reproductive toxicities, respectively) or the subset of compounds with in vitro and in vivo data (*n* = 51). We observe similar results for the relationships between in vitro activities and structural alerts, regardless of the size and composition of the datasets. The similar information content of the in vitro activities and the structural alerts is furthermore the reason for the almost identical overall agreement, sensitivities, and specificities of activities in vivo with either structural alerts or in vitro activities, with regard to the same subset of compounds (*n* = 51). Again, we observe no false-negative results, but \>50% false positives. The agreement is much less for the relationships between the entire dataset of activities in vivo (*n* = 240) and structural alerts. This is due to the in vivo mammalian dataset representing multiple pathways of reproductive toxicity, while the structural alerts are limited to EA receptor interactions.Table 6Overall agreement, sensitivities, and specificities of in vivo mammalian long-term reproductive toxicities, in vitro activities, and structural alerts of potential EA-EDs*n*Overall agreement (%)Sensitivity (%)Specificity (%)In vitro/structural alerts (all compounds with in vitro data)74479.883.777.1In vitro/structural alerts (all compounds with in vitro and in vivo data)5184.379.288.9In vivo/in vitro (all compounds with in vitro and in vivo data)5152.950.0100In vivo/structural alerts (all compounds with in vitro and in vivo data)5149.045.8100In vivo/structural alerts (all compounds with in vivo data)24020.015.4100Dataset *n* = 744: all compounds with in vitro data, dataset *n* = 240: all compounds with in vivo data, dataset *n* = 51: all compounds with in vitro and in vivo data

The screening for potential EA-EDs based on structural alerts relative to in vitro classifications and in vivo mammalian long-term reproductive toxicities is shown in Table [7](#Tab7){ref-type="table"}. Regarding first the chemicals with mammalian long-term reproductive toxicity in vivo and receptor-based in vitro assays, we see positive results from the three approaches confirming each other for 19 chemicals (marked in red). Five substances with in vivo mammalian long-term reproductive toxicity are identified in vitro but not from their chemical structures (marked in orange). Structural alerts classify another three compounds with activity in vivo but not in vitro (marked in orange). For the remaining 21 mammalian long-term reproductive toxicants, neither in vitro assays nor structural alerts provide evidence of interferences with EA endocrine receptors and, thus, other toxic pathways are more likely causing the reproductive toxicity.Table 7Screening for potential EA-EDs based on structural alerts relative to in vitro classifications and in vivo mammalian long-term reproductive toxicities (numbers of chemicals, *n* = 933)Color code: red: very high probability of EA-EDs, orange: high probability of EA-EDs, yellow: moderate probability of EA-EDs, pale yellow: low probability of EA-EDs, pale green: very low probability of EA-EDs, green: unlikely EA-EDs

For 13 chemicals that are inactive in vivo, we observe no structural alerts and also the in vitro data suggest the absence of EA endocrine effects (marked in green).

Among the 744 chemicals in the combined dataset with in vitro data are 693 without information about in vivo mammalian long-term reproductive toxicity, 335 of them with structural alerts and 358 without structural alerts. The evaluation of their in vitro activities in combination with structural alerts indicates 84 chemicals (marked in orange) with high probability of EA-EDs in fish and further assessments are recommended. Lower probability of EA-EDs may be associated with the chemicals with moderate to minor activity in vitro and/or the absence of structural alerts \[marked in (pale) yellow\]. The priority for further assessments is very low for the 313 substances with only very weak or no activity in vitro and without structural alerts (marked in pale green).

Application of structural alerts for the identification of potential EA-EDs in EINECS {#Sec10}
-------------------------------------------------------------------------------------

The structural alerts for the identification of potential EA-EDs (Table [2](#Tab2){ref-type="table"}) have been applied to EINECS (European inventory of existing commercial chemical substances) to test the performance on large numbers of diverse substances and to prioritize potential candidates for endocrine activity due to interactions with estrogen and androgen receptors. EINECS includes approx. 100,000 substances that were deemed to be on the European Community market between January 1, 1971 and September 18, 1981 \[[@CR31]\]. Substances listed in EINECS are "existing chemicals" and considered phase-in substances under REACH.

For application to EINECS, the structural alerts (Table [2](#Tab2){ref-type="table"}) have been implemented in a computerized screening tool (EDC-Scan).[1](#Fn1){ref-type="fn"} To support prediction confidence of the structural alerts in EDC-Scan, their applicability domain (AD) was defined based on atom-centered fragments (ACFs) \[[@CR32]\]. The collected dataset of estrogenic and androgenic activities in vitro (see Additional file [1](#MOESM1){ref-type="media"}) was used as the training set for the determination of the AD of the structural alerts. If a chemical is within the AD because it is similar to the substances used to set up the model, predictions are considered most trustworthy. If a compound is outside the AD, reliability of estimates is low because it may act in different ways.

More than 33,000 discrete organic EINECS compounds are within the ACF-defined AD of the structural alerts for potential EA-EDs. Among them, structural alerts indicate 3585 chemicals (ca. 11%) as candidates with potential endocrine activity. Their chemical structures are principally able to interact with estrogen and androgen receptors as either agonists or antagonists. Due to the possibility that these chemicals may interact with EA receptors, they should be subject to further investigations regarding their potential for endocrine effects in fish.

Structural alerts have been detected in another 413 organic chemicals that are outside the ACF-defined AD of the structural alerts for the identification of potential EA-EDs. According to good modeling practice, these predictions are not valid because they are not supported by the activities of the compounds of the training set. Still, these 413 chemicals contain structural elements that may be able to interact with estrogen and androgen receptors. If no additional evidence for endocrine activity is available, such alerts would probably not be sufficient to trigger further regulatory action such as substance evaluation, although toxicological reasoning suggests that they are candidates for EA-ED activities.

Estrogenic and androgenic ED activities of the remaining substances cannot be excluded, but are less likely. Because the structural alerts perform much better for substances with (very) high estrogenic and androgenic activities (\<10% false-negative classifications for strong binders) as compared to \>15% false-negative classifications for (very) weak binders, there is reasonable probability that the candidates with potential endocrine activities based on structural alerts include the most hazardous EA-EDs.

Conclusions {#Sec11}
===========

In vivo, in vitro, and in silico methods for the identification of potential EA-EDs with regard to the environment cover different adverse effects at the biomolecular and organism levels and indicate population-relevant effects. In vivo studies often summarize effects caused by multiple pathways of endocrine and other reproductive toxicities. In vitro assays may address specific modes of endocrine activities. Structural alerts represent the in vitro assays from which they were derived. The combination of in vivo and in vitro information with structural alerts provides complementary information for evidence-based assessments of potential EDs. Information obtained at each level may support the priority setting for further assessments of candidate chemicals with potential environmental hazards. Evidence for endocrine activity increases if structural alerts, in vitro activities, as well as in vivo information provide positive results.

Application of structural alerts for the identification of potential EDs to the EINECS inventory indicated 3585 chemicals (ca. 11%) as potential candidates for endocrine effects. Due to the possibility that these chemicals may interact with estrogen and androgen receptors, they should be subject to further investigations regarding their potential for endocrine activity with regard to the environment. Such substances are indicated during the mass screening performed by ECHA and manually screened by member states. They may become subject to regulatory actions if the screening evidence is substantiated by additional information.

Methods {#Sec12}
=======

Experimental data from in vitro assays {#Sec13}
--------------------------------------

Data were collected from publicly available databases and the open literature for in vitro tests on estrogenic and androgenic receptor binding and receptor activation in cell cultures. Activities were measured via reporter gene activation or cell proliferation, for example, competitive ligand-binding assays, reporter gene assays with mammalian cells with endogenous estrogen receptors transiently or permanently transfected with luciferase reporter gene systems, for example, CALUX \[[@CR33], [@CR34]\] and MVLN, MCF-7, or HeLa cells \[[@CR33], [@CR35]--[@CR38]\], yeast-based receptor gene tests stably transfected with a β-galactosidase reporter gene \[[@CR14]\], and MCF-7 cell proliferation assay (E-Screen) \[[@CR39]\].US Food and Drug Administration Endocrine Disruptor Knowledge Base (FDA-EDKB): <http://www.fda.gov/ScienceResearch/BioinformaticsTools/EndocrineDisruptorKnowledgebase/default.htm>.The FDA-EDKB database contains data regarding binding to androgen as well as estrogen receptors. The ligand-binding studies were conducted and validated at NCTR (National Center for Toxicological Research, Jefferson, USA). The test results are reported as percent relative binding affinity (RBA) of the test substance relative to the respective positive standards (17R-methyl-^3^H\]methyltrienolone (R1881) for AR and \[^3^H\]-17β-estradiol for ER).Androgen receptor (recombinant receptor): log (RBA) is given for 146 of 202 substances, ranging between 2.3 and −3.6. The remaining 56 substances are classified as non-binding.Estrogen receptor (isolated from rat uteri): log (RBA) is given for 131 of 232 substances, ranging between 2.6 and −4.5. The remaining 101 substances are classified as non-binding.National Center for Toxicological Research Estrogen Receptor Binding Database (DSSTOX-NCTRER): <http://www.epa.gov/ncct/dsstox/sdf_nctrer.html>.The DSSTOX-NCTRER database contains relative receptor-binding affinities for 232 chemical substances based on ligand-binding studies with estrogen receptors (species: rat). Activities are classified in five "activity categories". This dataset is identical with the estrogen receptor dataset of FDA-EDKB described above.Data retrieved from primary literature:Primary literature was evaluated for test results from diverse in vitro assays (Table [8](#Tab8){ref-type="table"}); 1155 test results were collected for 744 substances (data tables with references are provided in Additional file [1](#MOESM1){ref-type="media"}).Table 8Numbers of in vitro data retrieved from primary literatureIn vitro assaysNumber of test resultsReporter gene assays Androgen receptor activation, agonist93 Androgen receptor activation, antagonist395 Estrogen receptor activation, agonist ER alpha202 Estrogen receptor activation, antagonist ER alpha86 Estrogen receptor activation, agonist ER beta62 Estrogen receptor activation, antagonist ER beta7Ligand-binding assays Receptor-binding AR36 Receptor-binding ER alpha246 Receptor-binding ER beta28 Total1155*ER* estrogen receptor, *AR* androgen receptor

Classification statistics {#Sec14}
-------------------------

The results of pairwise comparisons of the in vivo, in vitro, and in silico classifications of potential EA-EDs were quantified in terms of accuracy (proportion of substances correctly classified), sensitivity (proportion of true positives correctly classified), and specificity (proportion of true negatives correctly classified):$$\documentclass[12pt]{minimal}
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Additional files {#Sec15}
================

**Additional file 1.** Estrogenic and androgenic endocrine activities in vitro. **Additional file 2.** Structural alerts. **Additional file 3.** False negatives (not recognized by structural alerts).

Within a follow-up project (UBA, FKZ 3714634120), the structural alerts for EA-EDs as well as other endocrine effects are being included in ChemProp (<http://www.ufz.de/ecochem/chemprop>).
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